• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    Veteran genomics leader joins Illumina to advance global medical strategy

    Illumina chief commercial officer to depart for role as a life science tools company CEO 

    SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data.

    Influential genomics leader Eric Green, MD, PhD, joins Illumina as Chief Medical Officer. As Illumina's medical leader, Dr. Green will help advance the clinical use of genomics globally, expanding access to precision medicine solutions around the world. Credit: Courtesy of Eric Green

    Dr. Green's unique expertise, knowledge, and influence with partners, KOLs, and medical professionals will serve as a critical component in Illumina's strategic efforts to improve human health through genomics on a global level. As CMO, Dr. Green will be part of Illumina's Executive Leadership Team and will be a champion for the company's mission, technology roadmap, and growing clinical impact. 

    "Eric is a once-in-a-generation leader in genomics whose career has closely tracked the evolution of the field itself," said Jacob Thaysen, chief executive officer of Illumina. "He has spent decades championing the role of genomics in medicine and building trust across the scientific, clinical, and public health communities. Eric's counsel will be invaluable in helping Illumina extend and deepen the medical impact of its innovations for people worldwide."

    Dr. Green is widely regarded as one of the most influential leaders in genomics since the field's inception. He joins Illumina after more than three decades at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health. As the NHGRI Director from 2009 to 2025, he helped guide the transformation of genomics from a primarily research-driven field into a foundational element of modern medicine and public health.

    "Illumina has been instrumental to the growth and evolution of genomics, and I am excited to join the company at a time when genomic information is becoming increasingly important in clinical care," said Dr. Green. "Illumina sits at the center of the growing omics ecosystem, and the company is uniquely positioned to help shape the next phase of genomic medicine."

    Dr. Green trained as a physician scientist, earning an M.D. and Ph.D. from Washington University School of Medicine. During his residency training in clinical pathology (laboratory medicine), he launched his career in genomics. Several years later, he became a beginning-to-end participant in the Human Genome Project and emerged as an international genomics leader.

    Illumina congratulates Everett Cunningham on appointment

    Illumina also announced the departure of chief commercial officer Everett Cunningham, who has been appointed as CEO of a life science tools company.

    "We are thankful for Everett's leadership during a crucial time of transition for Illumina. For our path forward, we have strong leadership in place, continue to make excellent progress towards our long-term goals, and are confident in our path forward," said Jacob Thaysen, chief executive officer at Illumina. Thaysen will act as interim chief commercial officer until a permanent successor to Cunningham is named. 

    Illumina will participate in next week's J.P. Morgan Healthcare Conference, where Jacob Thaysen, CEO, will speak on Tuesday, January 13, at 7:30 AM Pacific Time.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Illumina Investor Relations

    858-291-6421

    IR@illumina.com

    Media:

    Christine Douglass

    PR@illumina.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-dr-eric-green-as-chief-medical-officer-302656871.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    6/26/2026$185.00Mkt Perform
    Bernstein
    6/10/2026$185.00Neutral → Overweight
    Analyst
    5/15/2026$170.00Outperform
    RBC Capital Mkts
    5/14/2026$155.00Neutral → Outperform
    Daiwa Securities
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:25:34 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:22:10 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/25/26 9:41:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina expands Billion Cell Atlas program with new AI drug developers

    Partners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and

    7/16/26 12:00:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we

    7/9/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik

    7/9/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein resumed coverage on Illumina with a new price target

    Bernstein resumed coverage of Illumina with a rating of Mkt Perform and set a new price target of $185.00

    6/26/26 9:21:34 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina upgraded by Analyst with a new price target

    Analyst upgraded Illumina from Neutral to Overweight and set a new price target of $185.00

    6/10/26 8:16:12 AM ET
    $ILMN
    Medical Specialities
    Health Care

    RBC Capital Mkts resumed coverage on Illumina with a new price target

    RBC Capital Mkts resumed coverage of Illumina with a rating of Outperform and set a new price target of $170.00

    5/15/26 8:29:06 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    SEC Filings

    View All

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/26 9:08:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    5/26/26 5:28:17 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SD filed by Illumina Inc.

    SD - ILLUMINA, INC. (0001110803) (Filer)

    5/19/26 4:16:55 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik

    7/9/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare

    6/23/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we

    7/9/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results:Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%)GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases"Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Offic

    4/30/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care